Clinical Trials Browser

ACE-011 × Clear all

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT00747123 2024-10-03

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Phase 2 Completed

30 enrolled 15 charts

Multiple Myeloma

NCT01284348 2024-08-29

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

26 enrolled 18 charts

Classical hematologyGenitourinaryGynecologicHead & NeckThoracic

Anemia, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Small Cell Lung Carcinoma

NCT01712308 2023-10-10

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Phase 2 Completed

56 enrolled 9 charts

Classical hematologyMyeloid

Anemia, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT00931606 2023-09-13

MK-7962-012

Phase 2 Terminated

30 enrolled 32 charts

Classical hematology

Anemia, Neoplasm Metastasis, Neoplasms

NCT01736683 2022-10-24

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Phase 2 Completed

74 enrolled 33 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02230917 2016-09-01

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma